1.20

2.56% 0.03

Pre-market: 1.21 0.01 +0.83%

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.20, with a volume of 809.41K. It is up +2.56% in the last 24 hours and down -11.11% over the past month. Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Previous Close:

$1.17

Open:

$1.2

24h Volume:

809.41K

Relative Volume:

0.54

Market Cap:

$86.76M

Revenue:

Net Income/Loss:

$-44.95M

P/E Ratio:

-1.3445

EPS:

-0.8925

Net Cash Flow:

$-56.37M

1W Performance:

+4.35%

1M Performance:

-11.11%

6M Performance:

-10.45%

1Y Performance:

-49.15%

1-Day Range:

$1.18

$1.25

1-Week Range:

$1.10

$1.25

52-Week Range:

$0.8719

$3.08

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.20	86.76M	0	-44.95M	-56.37M	-0.8925
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Jun 14, 2026

Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com

Jun 14, 2026

Jun 12, 2026

[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan

Jun 12, 2026

Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan

Jun 12, 2026

Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan

Jun 12, 2026

Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan

Jun 12, 2026

Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Jun 12, 2026

Jun 11, 2026

Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan

Jun 11, 2026

Jun 10, 2026

BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView

Jun 10, 2026

BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView

Jun 10, 2026

Jun 09, 2026

Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Jun 09, 2026

Jun 08, 2026